Examining the 340B Drug Discount Program Controversy

This chapter explores the ongoing debate over the 340B drug discount program and its effects on hospital funding. It examines legal challenges from pharmaceutical companies and the shifting dynamics of healthcare financing in light of recent administrative changes.